ArticleESMO gastrointestinal oncology2024

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials.

A Cammarota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.